SEHK:2157
SEHK:2157Biotechs

Lepu Biopharma (SEHK:2157): Valuation in Focus After Landmark EGFR-Targeted ADC Approval

Lepu Biopharma (SEHK:2157) just received conditional marketing approval from China's National Medical Products Administration for an innovative EGFR-targeted antibody-drug conjugate to treat recurrent or metastatic nasopharyngeal carcinoma. This milestone is expected to generate global attention and increased investor interest. See our latest analysis for Lepu Biopharma. Lepu Biopharma’s momentum has certainly kept investors on their toes this year. After surging to a 148% year-to-date share...